Prelude Therapeutics Incorporated
Organization details
- Legal name
- Prelude Therapeutics Incorporated
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Wilmington
- Headquarters state / province
- Delaware
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- PRLD
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001678660
- EIN
- 81-1384762
Board of directors
-
David P. Bonita · DirectorSince 2023
- Since 2023
- Since 2023
-
Katina Dorton · DirectorSince 2025
-
Krishna Vaddi · Director · CEOSince 2023
-
Mardi Dier · DirectorSince 2023
-
Martin Babler · DirectorSince 2023
-
Paul A. Friedman · DirectorSince 2023
-
Paul C. Scherer · DirectorSince 2025
-
Victor Sandor · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
94.4%
-
99.8%
-
99.8%
Board connections
8 of this board's directors also sit on 22 other boards. 22 are in the same sector.
-
Kymera Therapeutics Inc. Same sectorvia Felix Baker, Julian Baker and Victor Sandor
-
Madrigal Pharmaceuticals Inc. Same sectorvia Felix Baker, Julian Baker and Paul A. Friedman
-
Neurogene Inc. Same sectorvia Felix Baker, Julian Baker and Martin Babler
-
TScan Therapeutics Inc. Same sectorvia Felix Baker, Julian Baker and Katina Dorton
-
ACADIA Pharmaceuticals Inc. Same sectorvia Felix Baker and Julian Baker
-
BeOne Medicines Ltd. Same sectorvia Felix Baker and Julian Baker
-
Bicycle Therapeutics plc Same sectorvia Felix Baker and Julian Baker
-
DBV Technologies S.A. Same sectorvia Felix Baker and Julian Baker
-
Denali Therapeutics Inc. Same sectorvia Felix Baker and Julian Baker
-
Immunocore Holdings plc Same sectorvia Felix Baker and Julian Baker
-
Incyte Corp. Same sectorvia Felix Baker and Julian Baker
-
Kiniksa Pharmaceuticals International plc Same sectorvia Felix Baker and Julian Baker
-
Kodiak Sciences Inc Same sectorvia Felix Baker and Julian Baker
-
Replimune Group Inc. Same sectorvia Felix Baker and Julian Baker
-
vTv Therapeutics Inc. Same sectorvia Felix Baker and Julian Baker
-
ADC Therapeutics SA Same sectorvia Victor Sandor
-
AbCellera Biologics Inc. Same sectorvia Victor Sandor
-
Alumis Inc. Same sectorvia Martin Babler
-
Fulcrum Therapeutics Inc. Same sectorvia Katina Dorton
-
ImageneBio Inc. Same sectorvia David P. Bonita
-
MapLight Therapeutics Inc. Same sectorvia Martin Babler
-
Oric Pharmaceuticals Inc. Same sectorvia Mardi Dier
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $24,999,997
- 4 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 27, 2026 | Rajeev M. Shah 10% owner | Other | −1,407,000 | — | — |
| Apr 21, 2026 | David P. Bonita Director, 10% owner | Open-market purchase | +1,689,189 | $4.44 | $7,499,999 |
| Apr 21, 2026 | OrbiMed Genesis GP LLC Director, 10% owner | Open-market purchase | +1,689,189 | $4.44 | $7,499,999 |
| Apr 21, 2026 | David P. Bonita Director, 10% owner | Open-market purchase | +1,126,126 | $4.44 | $4,999,999 |
| Apr 21, 2026 | OrbiMed Genesis GP LLC Director, 10% owner | Open-market purchase | +1,126,126 | $4.44 | $4,999,999 |
| Oct 4, 2025 | Jane Huang Officer (President, CMO) | Option exercise | +9,375 | — | — |
| Oct 4, 2025 | Jane Huang Officer (President, CMO) | Shares withheld for tax | −3,355 | $1.47 | $4,932 |
| Jul 4, 2025 | Jane Huang Officer (President, CMO) | Option exercise | +9,375 | — | — |
| Jul 4, 2025 | Jane Huang Officer (President, CMO) | Shares withheld for tax | −3,355 | $0.79 | $2,650 |
| Apr 4, 2025 | Jane Huang Officer (President, CMO) | Option exercise | +9,375 | — | — |
| Apr 4, 2025 | Jane Huang Officer (President, CMO) | Shares withheld for tax | −3,355 | $0.68 | $2,281 |
| Mar 25, 2025 | Combs Andrew Officer (Chief Chemistry Officer) | Open-market purchase | +100,000 | $0.69 | $69,000 |
| Mar 25, 2025 | Krishna Vaddi Director, Officer (CEO) | Open-market purchase | +675,000 | $0.69 | $465,750 |
| Mar 21, 2025 | Krishna Vaddi Director, Officer (CEO) | Open-market purchase | +15,000 | $0.73 | $10,950 |
| Mar 20, 2025 | Krishna Vaddi Director, Officer (CEO) | Open-market purchase | +5,416 | $0.73 | $3,954 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Prelude Therapeutics Incorporated
Who is the CEO of Prelude Therapeutics Incorporated?
Krishna Vaddi is Prelude Therapeutics Incorporated's CEO.
How many directors are on Prelude Therapeutics Incorporated's board?
Prelude Therapeutics Incorporated's board has 10 directors: David P. Bonita, Felix Baker, Julian Baker, Katina Dorton, Krishna Vaddi, Mardi Dier, Martin Babler, Paul A. Friedman, Paul C. Scherer and Victor Sandor.
Are Prelude Therapeutics Incorporated insiders buying or selling shares?
Over the last 12 months, Prelude Therapeutics Incorporated insiders bought $25.0 million of shares in 4 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="prelude-therapeutics-incorporated"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.